3129 T3D3087 Swainsonine Swainsonine is a plant toxin found in locoweed (families Fabaceae, Oxytropis, Astragalus and Swainsona) and some fungi (Metarhizium anisopliae, Rizoctonia leguminicola). It has been known to cause a potentially lethal central nervous system condition in livestock known as locoism and is a significant cause of economic losses in livestock industries. Along with slaframine, the other biologially active compound of R. leguminicola, it may contribute to a condition called "slobbers syndrome" in livestock that has ingested contaminated feed. (L1248, A3092) 72741-87-8 51683 C8H15NO3 173.105190 White powder. 143-144°C Oral, dermal, inhalation, and parenteral (contaminated drugs). (A3101) Swainsonine inhibits the activity of glycoside hydrolases, especially N-linked glycosylation. Inhibition of Golgi mannosidase II and other alpha-mannosidases causes the accumulation of atypical hybrid glycoproteins and oligosaccarides because the proper processing cannot occur. This also results in intracellular vacuolization. (L1248, A3092, A3093) No indication of carcinogenicity to humans (not listed by IARC). Swainsonine is a plant toxin found in locoweed (families Fabaceae, Oxytropis, Astragalus and Swainsona) and some fungi (Metarhizium anisopliae, Rizoctonia leguminicola). (L1248, A3092) Swainsonine causes a variety of neurological disorders, including locoism and "slobbers syndrome" in livestock. In man it causes a lysosomal storage disease, biochemically and morphologically similar to mannosidosis. It is also an appetite suppressant. (L1248, A3092, A3093) Symptoms of locoism include staggering gait, depression, muscular incoordination, staring, nervousness, hyperexcitability, loss of appetite, and reproductive alterations such as abortion and birth defects. The major symptom of "slobbers syndrome" is profuse salivation. Other symptoms include diarrhea, lacrimation, stiff joints, frequent urination, tremors, spontaneous abortion, labored breathing, loss of appetite, bloat, and possibly death. Swainsonine also causes vacuolation of most tissues. (L1819, A3092, A3093) 2009-07-23T18:26:10Z 2026-05-14T17:25:23Z C10173 Swainsonine DB02034 true OC1CN2CCCC(O)C2C1O C8H15NO3 InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2 FXUAIOOAOAVCGD-UHFFFAOYSA-N 173.2096 173.105193351 Exogenous Solid -1.4 5170 <p>William H. Pearson, Erik J. Hembre, &#8220;Method for preparing swainsonine.&#8221; U.S. Patent US5919952, issued December, 1986.</p> CHEM002424 DTXSID5046356 NS00037401 (1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol 63.93000000000001 43.117799999999995 18.1096065809744 0 4 3 13.284673320768636 9.470513713136212 1 2 -1.52 0.88 1.32e+03 g/l